Novartis delivers record earnings in first nine months of 2007
- Details
- Category: Novartis
Strong operational performance for Group continuing operations:
- Nine-month net sales up 13% to USD 28.1 billion (+9% local currencies) driven by all divisions, particularly Vaccines and Diagnostics and Sandoz
- Operating income rises 9% to USD 6.5 billion, excluding a one-time incremental environmental provision of USD 590 million to cover worldwide remediation plans
Strong sales growth in the first nine months of 2007
- Details
- Category: Roche
Group sales up 12% in local currencies to 33.9 billion Swiss francs. As anticipated, Tamiflu sales decline significantly in third quarter following completion of outstanding pandemic stockpiling orders. Full-year outlook reaffirmed: Group and Pharmaceuticals Division anticipate double-digit sales increases, and both divisions expect above-market growth; target is for Core Earnings per Share to grow faster than Group sales.
Pfizer Reports Third-Quarter 2007 Results
- Details
- Category: Pfizer
Third-Quarter 2007 Reported Diluted EPS of $0.11 Represents a Decline of 76% Compared to the Same Period Last Year and Includes Charges of $0.31 ($2.8 Billion Pre-Tax) Related to a Decision to Exit Exubera.
Adjusted Diluted EPS of $0.58 for the Third-Quarter 2007 Represents an Increase of 7% Compared to the Same Period a Year Ago.
Adjusted Diluted EPS of $0.58 for the Third-Quarter 2007 Represents an Increase of 7% Compared to the Same Period a Year Ago.
Novel agent for treatment of cerebral stroke and other diseases with neuronal damage
- Details
- Category: Lundbeck
H. Lundbeck A/S has initiated phase I clinical trials with the pharmaceutical candidate Lu AA24493 to investigate safety, tolerability and the pharmacokinetic profile of the compound in patients suffering from acute ischemic stroke.
Abbott Reports 14.4 Percent Sales Growth in Third Quarter
- Details
- Category: Abbott
Worldwide Pharmaceutical Sales Increased 19.6 Percent. Worldwide Medical Products Sales Increased 12.0 Percent. International Nutritionals Sales Increased 15.6 Percent. Company Confirms Earnings-Per-Share Outlook for 2007 and 2008.
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
- Details
- Category: Clinical Trials
Pharmion Corporation (Nasdaq: PHRM) today announced the initiation of an international pivotal Phase 3 clinical trial evaluating amrubicin, the Company's third-generation synthetic anthracycline, in the treatment of second-line small cell lung cancer (SCLC). The randomized, controlled, multi-center study will compare amrubicin to topotecan, the only approved chemotherapy for second-line treatment of SCLC in the US and EU. Enrollment in the study of 480 patients is underway.
Three-year analysis demonstrates continued robust treatment effect of Alemtuzumab compared to Rebif
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany, announced that top-line, three-year data from the CAMMS223 Phase II clinical trial comparing alemtuzumab with Rebif® (interferon beta-1a) for the treatment of multiple sclerosis were presented this weekend at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Prague. The results come from an analysis conducted at 36 months following treatment of 334 patients in the three-year trial.
More Pharma News ...
- Pfizer Engages with Nation's Physicians Through Sermo to Improve Patient Care
- Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
- Boehringer Ingelheim distinguished as number one Top Employer 2007 by Science Magazine
- Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
- Teva Announces Approval of Generic Actonel®
- EPO Rules European Nexium® Process Patent Valid
- Aptivus® (tipranavir) capsules granted full approval by the U.S. FDA